Developer docs
API playgroundTry for free, no card

Search company profiles

SoVarGen

Full company profile

uuid0000olw

Namestring
SoVarGen
Legal namestring
소바젠 주식회사 (Sovargen Co., Ltd.)
Websiteurl
sovargen.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

SoVarGen is a South Korean clinical-stage biotechnology company developing RNA-based therapeutics, principally antisense oligonucleotides (ASOs), for intractable neurological disorders caused by brain somatic mosaicism. Founded in 2018 by KAIST Professor Jeong Ho Lee and headquartered at the KAIST Munji Campus in Daejeon with a Seoul business development office, the company targets drug-resistant epilepsies (Focal Cortical Dysplasia Type II and Tuberous Sclerosis Complex epilepsy), pediatric brain tumors (BRAF-mutant low-grade glioma), and glioblastoma. The lead clinical-stage asset is SVG103 (paxalisib, an oral PI3K/mTOR inhibitor) in trials in Australia and Korea; SVG105 (ASO for FCD II epilepsy) is in IND-enabling studies; and SVG301 (ASO for BRAF-mutant LGG) and SVG104 (gene therapy for MOGHE) are in earlier research.

The company operates an integrated proprietary discovery platform called Sovarna, comprising three core technologies: Sovarin (ultra-low-frequency somatic mutation detection via the RePlow pipeline at VAF<1%), Sovarup (brain disease-specific translational models that introduce disease-causing somatic mutations into the same human cell types), and Sovaron (ASO drug discovery combining AI-driven sequence screening, high-throughput screening, neurotoxicity assessment, and translational efficacy validation). The platform is supported by a biorepository of over 3,000 patient brain tissue samples and 50+ peer-reviewed publications.

SoVarGen is pre-commercial and generates revenue through technology out-licensing and co-development partnerships with global pharmaceutical companies, supplemented by Korean government grants (e.g., KDDF). Revenue is realized as upfront payments, development and regulatory milestones, and royalties on commercialized products. The company's lead commercial milestone is a January 2026 technology transfer agreement with Angelini Pharma for the intractable epilepsy ASO candidate, valued at approximately 770 billion KRW (~$550M USD headline value), one of the largest Korean biotech licensing transactions. The company is preparing for a KOSDAQ IPO with NH Investment & Securities as lead underwriter.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersDaejeon, South Korea
HQ citystring
Daejeon
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
antisense oligonucleotide therapeutics, RNA therapeutics neurology, brain somatic mutations, intractable epilepsy treatment, CNS drug discovery
Industry4 codes
PRIMARYHLAAADAC
Antisense Oligonucleotides (ASO) Therapeutics (splice modulation/knockdown)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAG
RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAH
RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAE
RNA Chemistry & Oligonucleotide Engineering (backbones, modifications, stereochemistry)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Services-Commercial Physical & Biological Research8731
Product category
RNA Therapeutics / CNS Drug Discovery
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Technology Licensing / Out-licensing
TypeLicensing Royalties
Description

The company generates revenue through licensing its proprietary ASO candidates and platform technology to global pharmaceutical partners. Revenue is realized through upfront payments, milestone payments tied to development, regulatory, and commercial achievements, and potential royalties on product sales.

sovargen.com
2Co-development Partnerships
TypeLicensing Royalties
Description

Collaborative development agreements with pharmaceutical partners where development costs are shared, and the company contributes its proprietary platform and pipeline assets in exchange for development funding and future royalties.

sovargen.com
3Research Grants
TypeSubscription Recurring
Description

Government and institutional grants supporting early-stage research and platform development, including KDDF and other Korean government funding programs.

sovargen.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 4 records shown
1Sovarna
Description

Proprietary ASO drug discovery platform for intractable brain diseases caused by somatic mutations, comprising three core technologies: Sovarin (mutation detection), Sovarup (translational research models), and Sovaron (ASO drug discovery).

sovargen.com
+3 more records
Core offering1 text field

SoVarGen develops antisense oligonucleotide (ASO) RNA therapeutics and a proprietary drug discovery platform (Sovarna®) targeting intractable neurological disorders caused by brain somatic mutations. The company integrates ultra-low frequency mutation detection, disease-specific translational models, and AI-driven ASO design to deliver first-in-class drug candidates for focal epilepsy, brain tumors, and neurodegenerative diseases. Revenue is generated primarily through out-licensing of platform technology and pipeline assets to global pharmaceutical partners.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Technology transfer deal valued at 7,500-7,800 billion KRW with Angelini Pharma for epilepsy ASO treatment.
+1 more record
Product overview1 text field

SoVarGen is a biotechnology company developing RNA therapeutics for neurological disorders caused by brain somatic mosaicism. The company operates its proprietary Sovarna platform, which integrates three core technologies: Sovarin (ultra-low frequency mutation detection), Sovarup (brain disease-specific translational research models), and Sovaron (AI-powered ASO drug discovery). The product portfolio includes multiple pipeline candidates: SVG103 (paxalisib, a PI3K/mTOR inhibitor in clinical trials for TSC epilepsy), SVG105 (ASO for FCD II epilepsy in IND-enabling studies), SVG301 (ASO for BRAF-mutant LGG), and SVG104 (gene therapy for MOGHE). The platform enables first-in-class drug development targeting the root genetic drivers of intractable brain diseases through precision ASO medicines.

Product and service1 record
1Sovarna® Platform
Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-01-22
Description

Major technology licensing agreement for SoVarGen's ASO-based intractable epilepsy treatment. Described as a 7,500-7,800 billion KRW deal (approximately $5.5-5.8 billion USD), representing one of the largest biotech licensing deals from Korea. Angelini Pharma is a global pharmaceutical company focused on Brain Health, operating across 21 countries with €1.6 billion in revenue.

2지엘팜텍 (Gyeong Dong Pharmaceutical Tech)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-09-03
Description

Co-development partner for SDF01 formulation development. SDF01 is a pediatric intractable epilepsy (Focal Cortical Dysplasia) drug candidate repurposed from an existing marketed drug, with Phase 2 investigator-initiated trial in progress.

sovargen.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Partner for SVG103 (paxalisib) clinical development. SVG103 is an oral small-molecule PI3K/mTOR inhibitor for TSC2-associated epilepsy treatment. Clinical trials ongoing in Australia and Korea.

4MOTIR Therapeutics
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Partner for SVG304 (ASO for GBM) development program targeting glioblastoma with ASO therapy approach.

sovargen.com
5World-Renowned Hospitals and Brain Banks
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Strategic collaborations with world-renowned hospitals, research institutes, and brain banks enabling access to over 3,000 patient brain tissue samples integrated with comprehensive clinical records. Essential for Sovarin mutation detection technology validation.

sovargen.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Stoke Therapeutics is the most direct comparable: an ASO-focused biotech targeting CNS diseases caused by genetic mutations, with a lead program (STK-001) for Dravet syndrome and expansion into autosomal dominant optic atrophy. Both companies use ASOs to address root genetic causes of intractable neurological diseases, with similar scientific premise and delivery approaches.

TypeDirect peer
Description

Ionis is the pioneer and commercial leader in antisense oligonucleotide technology, with multiple approved ASO drugs (Spinraza, Tegsedi, Waylivra) and a broad CNS pipeline. SoVarGen's Sovaron ASO discovery platform directly competes with Ionis's chemistry and design capabilities, and Ionis serves as the benchmark for ASO platform valuations.

TypeDirect peer
Description

Wave Life Sciences develops stereopure oligonucleotide therapeutics (ASO and siRNA) with a focus on neurological diseases including Huntington's disease and ALS. Comparable to SoVarGen in modality (ASO) and CNS focus, with similar platform-plus-pipeline business model.

TypeBroad incumbent
Description

Biogen commercializes Spinraza (nusinersen), the leading intrathecal ASO for SMA, and has a broad neurology portfolio. As the established commercial leader in CNS ASOs, Biogen represents both a potential acquirer/partner for SoVarGen and a benchmark for commercial scalability of intrathecal ASO therapies.

TypeEmerging player
Description

PepGen develops conjugated oligonucleotides for neuromuscular and CNS diseases with enhanced cellular uptake. It represents an emerging player in CNS-targeted oligonucleotide therapeutics, addressing similar delivery challenges to SoVarGen's intrathecal approach.

TypeBroad incumbent
Description

Alnylam is the leading siRNA (RNA interference) therapeutics company with multiple approved products and a CNS pipeline. While siRNA is a related but distinct RNA therapeutic modality, Alnylam serves as a key comparable for RNA therapeutics platform valuations and pipeline economics.

TypeBroad incumbent
Description

BridgeBio develops therapeutics for genetic diseases including CNS indications (e.g., CALR-mutant myelofibrosis, transthyretin amyloidosis with CNS involvement). Comparable in rare disease focus and genetic target validation approach.

8SK Biopharmaceuticals
TypeRegional player
Description

SK Biopharmaceuticals is a Korean pharmaceutical company focused on CNS therapeutics, with FDA-approved Xcopri for epilepsy and an active licensing/out-licensing business model. Most relevant Korean regional peer for SoVarGen's neurology focus and licensing-led GTM.

TypeRegional player
Description

Hanmi Pharmaceutical is a major Korean pharma with neurological and rare disease pipelines and significant licensing deal experience. Comparable as a regional Korean peer with platform-based drug discovery and partnership-driven commercialization.

TypeEmerging player
Description

Marinus Pharmaceuticals develops CNS therapeutics for rare seizure disorders (CDKL5 deficiency disorder, tuberous sclerosis complex) with ganaxolone. Directly comparable to SoVarGen's TSC epilepsy focus (SVG103) and broader refractory epilepsy pipeline.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

SoVarGen

RNA Therapeutics / CNS Drug Discoverysovargen.com

What SoVarGen does

SoVarGen is a South Korean clinical-stage biotechnology company developing RNA-based therapeutics, principally antisense oligonucleotides (ASOs), for intractable neurological disorders caused by brain somatic mosaicism. Founded in 2018 by KAIST Professor Jeong Ho Lee and headquartered at the KAIST Munji Campus in Daejeon with a Seoul business development office, the company targets drug-resistant epilepsies (Focal Cortical Dysplasia Type II and Tuberous Sclerosis Complex epilepsy), pediatric brain tumors (BRAF-mutant low-grade glioma), and glioblastoma. The lead clinical-stage asset is SVG103 (paxalisib, an oral PI3K/mTOR inhibitor) in trials in Australia and Korea; SVG105 (ASO for FCD II epilepsy) is in IND-enabling studies; and SVG301 (ASO for BRAF-mutant LGG) and SVG104 (gene therapy for MOGHE) are in earlier research.

The company operates an integrated proprietary discovery platform called Sovarna, comprising three core technologies: Sovarin (ultra-low-frequency somatic mutation detection via the RePlow pipeline at VAF<1%), Sovarup (brain disease-specific translational models that introduce disease-causing somatic mutations into the same human cell types), and Sovaron (ASO drug discovery combining AI-driven sequence screening, high-throughput screening, neurotoxicity assessment, and translational efficacy validation). The platform is supported by a biorepository of over 3,000 patient brain tissue samples and 50+ peer-reviewed publications.

SoVarGen is pre-commercial and generates revenue through technology out-licensing and co-development partnerships with global pharmaceutical companies, supplemented by Korean government grants (e.g., KDDF). Revenue is realized as upfront payments, development and regulatory milestones, and royalties on commercialized products. The company's lead commercial milestone is a January 2026 technology transfer agreement with Angelini Pharma for the intractable epilepsy ASO candidate, valued at approximately 770 billion KRW (~$550M USD headline value), one of the largest Korean biotech licensing transactions. The company is preparing for a KOSDAQ IPO with NH Investment & Securities as lead underwriter.

SoVarGen firmographics

Firmographics
Name
SoVarGen
Legal name
소바젠 주식회사 (Sovargen Co., Ltd.)
Website
https://sovargen.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

SoVarGen industry classification

Industry
Product category
RNA Therapeutics / CNS Drug Discovery
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAADAC
Antisense Oligonucleotides (ASO) Therapeutics (splice modulation/knockdown)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAG
RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAH
RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAE
RNA Chemistry & Oligonucleotide Engineering (backbones, modifications, stereochemistry)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)

Keywords

  • Antisense oligonucleotide therapeutics
  • RNA therapeutics neurology
  • Brain somatic mutations
  • Intractable epilepsy treatment
  • CNS drug discovery

Where SoVarGen is headquartered

Location

Headquarters

HQ city
Daejeon
HQ country
South Korea
HQ region
Asia

Offices2 records

Markets served

SoVarGen business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Technology Licensing / Out-licensing: The company generates revenue through licensing its proprietary ASO candidates and platform technology to global pharmaceutical partners. Revenue is realized through upfront payments, milestone payments tied to development, regulatory, and commercial achievements, and potential royalties on product sales.
  2. Co-development Partnerships: Collaborative development agreements with pharmaceutical partners where development costs are shared, and the company contributes its proprietary platform and pipeline assets in exchange for development funding and future royalties.
  3. Research Grants: Government and institutional grants supporting early-stage research and platform development, including KDDF and other Korean government funding programs.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

SoVarGen product offering

Product offering

Core offering

SoVarGen develops antisense oligonucleotide (ASO) RNA therapeutics and a proprietary drug discovery platform (Sovarna®) targeting intractable neurological disorders caused by brain somatic mutations. The company integrates ultra-low frequency mutation detection, disease-specific translational models, and AI-driven ASO design to deliver first-in-class drug candidates for focal epilepsy, brain tumors, and neurodegenerative diseases. Revenue is generated primarily through out-licensing of platform technology and pipeline assets to global pharmaceutical partners.

Product overview

SoVarGen is a biotechnology company developing RNA therapeutics for neurological disorders caused by brain somatic mosaicism. The company operates its proprietary Sovarna platform, which integrates three core technologies: Sovarin (ultra-low frequency mutation detection), Sovarup (brain disease-specific translational research models), and Sovaron (AI-powered ASO drug discovery). The product portfolio includes multiple pipeline candidates: SVG103 (paxalisib, a PI3K/mTOR inhibitor in clinical trials for TSC epilepsy), SVG105 (ASO for FCD II epilepsy in IND-enabling studies), SVG301 (ASO for BRAF-mutant LGG), and SVG104 (gene therapy for MOGHE). The platform enables first-in-class drug development targeting the root genetic drivers of intractable brain diseases through precision ASO medicines.

Differentiator

Problem solved

Functional benefit

Brands

  • Sovarna: Proprietary ASO drug discovery platform for intractable brain diseases caused by somatic mutations, comprising three core technologies: Sovarin (mutation detection), Sovarup (translational research models), and Sovaron (ASO drug discovery).
  • Sovarin
  • Sovarup
  • Sovaron

Products and services

  • Sovarna® Platform

Quantifiable outcome

  • Technology transfer deal valued at 7,500-7,800 billion KRW with Angelini Pharma for epilepsy ASO treatment.
  • +1 more outcomes

Companies that use SoVarGen

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles2 records

SoVarGen technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature4 records

SoVarGen partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered flagship, core and minor.

  • Angelini PharmaflagshipStrategic or Co-development Partner · 22 January 2026Major technology licensing agreement for SoVarGen's ASO-based intractable epilepsy treatment. Described as a 7,500-7,800 billion KRW deal (approximately $5.5-5.8 billion USD), representing one of the largest biotech licensing deals from Korea. Angelini Pharma is a global pharmaceutical company focused on Brain Health, operating across 21 countries with €1.6 billion in revenue.
  • 지엘팜텍 (Gyeong Dong Pharmaceutical Tech)coreStrategic or Co-development Partner · 3 September 2020Co-development partner for SDF01 formulation development. SDF01 is a pediatric intractable epilepsy (Focal Cortical Dysplasia) drug candidate repurposed from an existing marketed drug, with Phase 2 investigator-initiated trial in progress.
  • Kazia TherapeuticsminorStrategic or Co-development PartnerPartner for SVG103 (paxalisib) clinical development. SVG103 is an oral small-molecule PI3K/mTOR inhibitor for TSC2-associated epilepsy treatment. Clinical trials ongoing in Australia and Korea.
  • MOTIR TherapeuticsminorStrategic or Co-development PartnerPartner for SVG304 (ASO for GBM) development program targeting glioblastoma with ASO therapy approach.
  • World-Renowned Hospitals and Brain BankscoreStrategic or Co-development PartnerStrategic collaborations with world-renowned hospitals, research institutes, and brain banks enabling access to over 3,000 patient brain tissue samples integrated with comprehensive clinical records. Essential for Sovarin mutation detection technology validation.

Scale indicators5 records

Recent moves8 records

Expansion highlights6 records

SoVarGen competitors and assessment

Company assessment

Direct peers

  • Stoke Therapeutics: Stoke Therapeutics is the most direct comparable: an ASO-focused biotech targeting CNS diseases caused by genetic mutations, with a lead program (STK-001) for Dravet syndrome and expansion into autosomal dominant optic atrophy. Both companies use ASOs to address root genetic causes of intractable neurological diseases, with similar scientific premise and delivery approaches.
  • Ionis Pharmaceuticals: Ionis is the pioneer and commercial leader in antisense oligonucleotide technology, with multiple approved ASO drugs (Spinraza, Tegsedi, Waylivra) and a broad CNS pipeline. SoVarGen's Sovaron ASO discovery platform directly competes with Ionis's chemistry and design capabilities, and Ionis serves as the benchmark for ASO platform valuations.
  • Wave Life Sciences: Wave Life Sciences develops stereopure oligonucleotide therapeutics (ASO and siRNA) with a focus on neurological diseases including Huntington's disease and ALS. Comparable to SoVarGen in modality (ASO) and CNS focus, with similar platform-plus-pipeline business model.

Broad incumbents

  • Biogen: Biogen commercializes Spinraza (nusinersen), the leading intrathecal ASO for SMA, and has a broad neurology portfolio. As the established commercial leader in CNS ASOs, Biogen represents both a potential acquirer/partner for SoVarGen and a benchmark for commercial scalability of intrathecal ASO therapies.
  • Alnylam Pharmaceuticals: Alnylam is the leading siRNA (RNA interference) therapeutics company with multiple approved products and a CNS pipeline. While siRNA is a related but distinct RNA therapeutic modality, Alnylam serves as a key comparable for RNA therapeutics platform valuations and pipeline economics.
  • BridgeBio Pharma: BridgeBio develops therapeutics for genetic diseases including CNS indications (e.g., CALR-mutant myelofibrosis, transthyretin amyloidosis with CNS involvement). Comparable in rare disease focus and genetic target validation approach.

Emerging players

  • PepGen: PepGen develops conjugated oligonucleotides for neuromuscular and CNS diseases with enhanced cellular uptake. It represents an emerging player in CNS-targeted oligonucleotide therapeutics, addressing similar delivery challenges to SoVarGen's intrathecal approach.
  • Marinus Pharmaceuticals: Marinus Pharmaceuticals develops CNS therapeutics for rare seizure disorders (CDKL5 deficiency disorder, tuberous sclerosis complex) with ganaxolone. Directly comparable to SoVarGen's TSC epilepsy focus (SVG103) and broader refractory epilepsy pipeline.

Regional players

  • SK Biopharmaceuticals: SK Biopharmaceuticals is a Korean pharmaceutical company focused on CNS therapeutics, with FDA-approved Xcopri for epilepsy and an active licensing/out-licensing business model. Most relevant Korean regional peer for SoVarGen's neurology focus and licensing-led GTM.
  • Hanmi Pharmaceutical: Hanmi Pharmaceutical is a major Korean pharma with neurological and rare disease pipelines and significant licensing deal experience. Comparable as a regional Korean peer with platform-based drug discovery and partnership-driven commercialization.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

SoVarGen financial estimates

Financial estimate

Revenue estimate

Valuation estimate

SoVarGen leadership team

Management profile

Number of profiles

Profiles7 records

SoVarGen funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

SoVarGen M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SoVarGen

What does SoVarGen do?

SoVarGen develops antisense oligonucleotide (ASO) RNA therapeutics and a proprietary drug discovery platform (Sovarna®) targeting intractable neurological disorders caused by brain somatic mutations. The company integrates ultra-low frequency mutation detection, disease-specific translational models, and AI-driven ASO design to deliver first-in-class drug candidates for focal epilepsy, brain tumors, and neurodegenerative diseases. Revenue is generated primarily through out-licensing of platform technology and pipeline assets to global pharmaceutical partners.

Is SoVarGen a public or private company?

SoVarGen is a private company. It is classified as venture growth investor backed and is currently operating.

When was SoVarGen founded?

SoVarGen was founded in 2018. It employs 11 to 50 people.

Where is SoVarGen based?

SoVarGen is headquartered in Daejeon, South Korea, in the Asia region.

How does SoVarGen make money?

Three revenue lines are on record. Technology Licensing / Out-licensing is the primary driver. The others are co-development Partnerships and research Grants.

Who are SoVarGen's main competitors?

Direct peers on record are Stoke Therapeutics, Ionis Pharmaceuticals and Wave Life Sciences. Broad incumbents are Biogen, Alnylam Pharmaceuticals and BridgeBio Pharma. Emerging players are PepGen and Marinus Pharmaceuticals. Regional players are SK Biopharmaceuticals and Hanmi Pharmaceutical.

Does SoVarGen have an API?

No public API is recorded for SoVarGen.

What industry is SoVarGen in?

SoVarGen's product category is RNA Therapeutics / CNS Drug Discovery. Its primary akta.pro industry code is HLAAADAC, Antisense Oligonucleotides (ASO) Therapeutics (splice modulation/knockdown), with a secondary code of HLAAADAG, RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales